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To investigate proteins expressed in the renal tissue of the passive Heymann nephritis (pHN) rat model, we prepared pHN rat 
models with anti-FxA1 serum and analyzed the proteins differentially expressed in the kidney tissue with label-free liquid chro-
matography-tandem mass spectrometry. We then analyzed in depth the endoplasmic reticulum stress (ERS)-related protein using 
an online bioinformatics platform. Forty-one differential proteins and their annotations were obtained. Gene Ontology (GO) func-
tion analysis showed that 16 proteins were involved in cellular metabolism and 22 were proteins related to catalytic activity, in-
cluding protein folding or ATPase. Protein-GO networks indicated that VCP could interact with the ERS marker HSPa5, with 
both involved in a single pathway. On inhibition of podocyte VCP by RNAi under normal conditions, the HSPa5 expression level 
did not change, but when the cell was subjected to ERS by tunicamycin, HSPa5 expression significantly increased with RNAi of 
VCP when compared with the tunicamycin-treated group. Our results showed that ERS plays an important role in podocyte injury 
of membranous nephropathy and is mediated by an HSPa5-VCP signaling pathway, in which the most predominant proteins are 
those related to cellular metabolism and catalytic activity. 
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Membranous nephropathy (MN), a common nephrotic syn-
drome in adults, is an important cause of chronic kidney 
disease [1,2]. The distinctive pathologic feature of MN is 
the presence of immune deposits beneath podocytes [3]. 
The mechanism of podocyte damage is thought to be quite 
complex, involving activation of complement and cytokines, 
oxidative stress, and autophagy. The passive Heymann ne-
phritis (pHN) model is the most commonly used animal 
model to simulate the conditions of MN [4,5]. Although 
previous studies have used the pHN model to analyze the 
mechanism of MN development at multiple sites, few have 
focused on the gene changes of the entire kidney. The current 
study therefore analyzed differentially expressed proteins of 
the pHN rat model with high-throughput technology.  
In the past, mass spectrometry (MS) has been of little use 
in quantifying differential proteins, being limited to mainly 
qualitative research. Recently, however, comparative quan-
tification of label-free liquid chromatography (LC)-MS pro-
teomics data has emerged as an alternative approach [6]. 
Label-free quantification [7] MS can determine the differ-
ential expression of proteins. In this method, proteins are 
compared based on the intensities of extracted ion chroma-
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tograms from complex samples such as enzymatic digests. 
This method does not require metabolic, chemical, or en-
zymatic labeling or premixing of the samples [8]. Multiple 
data sets, typically run in triplicate, are aligned using mass 
and LC elution time, which improves the sensitivity and 
accuracy of results when compared with the traditional two- 
dimensional technology [9–11]. Therefore, label-free quan-
tification MS has the advantages of convenience and relia-
ble protein quantification and identification.  
This study on the pHN rat model used label-free quanti-
tative MS for high-throughput identification of differentially 
expressed proteins at several time points. The endoplasmic 
reticulum stress (ERS)-related protein was then analyzed in 
depth using the online analysis platform found at http:// 
www.uniprot.org and http://bioinfo.capitalbio.com/mas3.0/.  
1  Materials and methods 
1.1  Experimental animals 
Nine 180–200 g male SD (Sprague-Dawley) rats were pur-
chased from Beijing Huafukang Company and divided into 
three groups containing three animals each: control, 14 d 
postinjection, and 21 d postinjection. Experimental animals 
were housed under specific pathogen-free conditions: 22± 
1°C, 40% humidity, 12-h:12-h light/dark cycle, and free 
access diet. The study was approved by the Institutional 
Animal Care and Use Committee at the Chinese PLA Gen-
eral Hospital and Military Medical Postgraduate College.  
1.2  Reagents 
Reagents used were acetonitrile (AN; Fisher Scientific, 
Waltham, MA, USA), formic acid (FA; Fisher Scientific), 
dithiothreitol (DTT; Sigma, St. Louis, MO, USA), iodoace-
temide (IAA; Amresco, Solon, OH, USA), NH4HCO3 (Sigma), 
trypsin enzymolysis liquid (Promega, Madison, WI, USA), 
BCA protein concentration detection reagent kit (Pierce, 
Rockford, IL, USA), tunicamycin (Tm; Sigma), rabbit pol-
yclonal anti-HSPa5, VCP antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA), and anti-rabbit IgG (Santa 
Cruz Biotechnology). 
1.3  Preparation and confirmation of PHN model  
Tubular brush border extracts and anti-Fx1A serum was 
prepared according to the literature [12–14]. Antisera at   
1 mL/100 g (titer 1:250) were given as an initial tail vein 
injection, followed by a second dose 1 h later and one fur-
ther booster injection. The control group received intrave-
nous injection of the same dose of saline. All pHN rats had 
heavy proteinuria (urine protein >100 mg/d; normal <20). 
At 14 and 21 d after injection, rats were anesthetized by 
intraperitoneal injection of 2% sodium pentobarbital (40 
mg/kg) prior to collection of kidney tissue samples.  
1.4  Cell culture and siRNA transfection 
Preserved mouse podocytes (MPCs) provided by Dr. Peter 
Mundel (University of Miami, Miami, FL, USA) were cul-
tured as described previously [15]. Differentiated podocytes 
were treated with 2.5 ng/mL Tm (Sigma) for 10 h to induce 
the ERS.   
siRNA-targeting VCP was purchased from Santa Cruz 
Biotechnology (cat. sc-37188). The siRNA was transfected 
into MPCs by Jetprime Polyplus transfection reagent (Poly-
plus-transfection Inc., New York, NY, USA) according to 
the manufacturers’ recommendations. 
1.5  Protein preparation 
Kidney tissues were lysed in buffer solution (50 mmol/L 
Tris-HCl (pH 7.6), 150 mmol/L NaCl, 1% NP-40, 0.1% so-
dium dodecyl sulfate (SDS), 0.5% deoxycholic acid, 1 
g/mL leupeptin, 1 g/mL aprotinin, and 0.5 mmol/L phe-
nylmethylsulfonyl fluoride), then cooled on ice for 30 min 
prior to centrifuging at 12000 r/min for 30 min at 4°C. The 
supernatant was removed and the protein concentration was 
determined by the BCA method (Bio-Rad, Hercules, CA, 
USA). Then 10 mmol/L DTT was incubated with 100 g 
protein at 56°C for 1 h. After cooling to room temperature, 
the protein was alkalized by 50 mmol/L IAM in darkness 
for 45 min. Excess IAM was removed with 40 mmol/L DTT 
at room temperature. The sample was further diluted five 
times with 25 mmol/L NH4HCO3. Trypsin 1% was added to 
digest the protein for 12 and 6 h at 37°C. FA 0.1% was used 
to terminate digestion, and the debris was removed by cen-
trifugation at 13000 r/min for 10 min. The supernatant was 
stored at 80°C for MS analysis. 
1.6  LC-MS analysis 
The multidimensional protein identification system is com-
posed of an LTQ-ion trap (ThermoFisher Scientific, Wal-
tham, USA) mass spectrometer with an electrospray ioniza-
tion (nano-ESI) source. We have performed LC-MS analy-
sis previously [16]. Briefly, 100 g of digested peptides 
were pre-fractionated then were injected onto a self-made 
biphasic capillary column by high-pressure nitrogen. The 
mobile phase consists of three solutions: A (5% AN, 0.1% 
FA), B (80% AN, 0.1% FA), and C (800 mmol/L ammo-
nium acetate, 5% AN, 0.1% FA). Solution A was used to 
desalt the biphasic capillary column for 45 min, after which 
solution C was used to wash it stepwise, with the concentra-
tion of ammonium acetate increasing from 0 to 800 mmol/L. 
The elution from the column was loaded onto a C18 analyt-
ical capillary chromatography column and a fraction from 
the column was ionized by electrospray for MS analysis. 
The spray voltage was set to 2.0 kV, and the temperature of 
the heated capillary was set to 200°C. MS data were col-
lected in a data-dependent acquisition mode. Parameters 
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related to MS/MS data acquisition were set as follows: 
normalized collision energy 35%, ion selection threshold 
200 counts, activation Q 0.250, activation time 30 ms, and 
dynamic exclusion time 30 s. The elution gradient of HPLC 
and MS scanning were controlled by XCalibur (Fisher Sci-
entific). 
1.7  Data processing and protein identification 
LC-MS data were processed using Progenesis LC‑MS soft-
ware (Nonlinear Dynamics Corp., Newcastle upon Tyne, UK) 
using the default settings. Proteins were identified using the 
NCBI rat database (March 2011). The GI number of pro-
teins was transformed into UniProtKB on http://www.uniprot. 
org [17]. Pathway networks and protein functional grouping 
were generated by the online platform at http://bioinfo.cap-     
italbio.com/mas3.0/. 
1.8  Western blotting 
Fifty micrograms of total protein was separated by 7.5% 
SDS-PAGE, transferred to a membrane, and blocked with 
5% skim milk, probed with primary antibody for 2 h at 
room temperature, and incubated with horseradish peroxi-
dase-conjugated secondary antibody. -actin was used for 
the sample control. Immunoreactive bands were visualized 
using an enhanced chemiluminescent system.  
1.9  Real-time PCR assay 
RNA was extracted from tissues and cells using TRIzol 
reagent (Invitrogen, Carlsbad, CA, USA) and was reverse 
transcribed to cDNA using M-MLV reverse transcriptase  
(2 g) (Invitrogen). The cDNA was used as a template in 
quantitative real-time PCR reactions performed using Taq-
Man PCR Master Mix and an ICycler system (Bio-Rad). 
The following primers and probe were designed from the 
full-length VCP mRNA sequence and synthesized by SBS 
Biotechnology Corp. (Beijing, China): sense, 5′-AAACC-     
GTGGTAGAGGTGCCA-3′; antisense, 5′-CTTGGAAGG-     
TGTCATGCCAA-3′; and TaqMan probe, 5′-FAMCAGT-      
ATCCTGTGGAGCACCCAGACAAATTCTAMRA-3′. As 
an internal control, rat GAPDH was amplified using the 
following: sense, 5′-GGCATGGACTGTGGTCATGAG-3′; 
antisense, 5′-TGCACCACCAACTGCTTAGC-3′; and Taq-    
Man probe, FAM-5′-CCTGGCCAAGGTCATCCATGACA-  
ACTTTAMRA-3′. Relative expression (fold-change vs. con-
trol) was quantified by the 2Ct method [18].  
1.10  Statistical processing 
All data were analyzed using SPSS 13.0 (SPSS Inc., Chi-
cago, IL, USA) software; data are expressed as the mean ± 
SD. The differences between the two groups were compared 
with ANOVA, and P < 0.05 was considered statistically 
significant. 
2  Results 
2.1  LC-MS analysis results  
There were 2134 total proteins and 234 differentially ex-
pressed proteins in all three experimental groups. Of those, 
41 had 20 > NRatio > 1.5 (upregulation) or 0.05 < NRatio < 
0.66 (downregulation) (NRatio: the change ratio of the up/ 
down-regulated protein on day 14 or 21 versus control). 
Five proteins have not been annotated in the Uniprot data-
base, including rCG25753 isoform CRA_b, rCG53940 iso-
form CRA_a, aldolase B isoform CRA_a, rCG55135 iso-
form CRA_c, and alanine-glyoxylate aminotransferase 2 
isoform CRA_c, and 36 proteins have the corresponding 
Uniprot ID. Table 1 shows how the proteins were grouped. 
2.2  Classification of differentially expressed proteins 
All differentially expressed proteins, upregulated or down-
regulated at day 14 or 21, were classified into three groups, 
A, B, and C. Proteins in group A were downregulated at day 
14, but upregulated at day 21; group B showed downregula-
tion at days 14 and 21; and group C showed upregulation at 
days 14 and 21. As shown in Figure 1, group A contained 
UK114, B4F768, CALB1, THIM, OAT, COTL1, Q68FT4, 
ACTN4, DECR, D3ZZN3, Q66HT1, Q63011, ACON, 
Q3MHS9, HSP7C, ADT2, Q6AYS2, and Q7TMC7; group 
B contained DCXR, GSH0, GRP75, Q9QYA6, ATPB, 
XYLB, G3V826, GRP78g and GSH1; and group C con-
tained NIT2, IDHC, AATC, Q7TP54, TERA, ST1C2, 
D4A2K1, AASS, and GSHR.  
2.3  Gene Ontology analysis of differentially expressed 
proteins 
Differentially expressed proteins were analyzed according 
to the Gene Ontology (GO) classification. As shown in Fig-
ure 2(a), among these proteins, 23 contributed to cellular 
structure, 30 to molecular function, and 22 to biological 
processes. The subgroup analysis is shown in Figure 2(b)– 
(d). In the biological process category, proteins related to 
cellular processes have the highest incidence with 19 pro-
teins. In this subgroup, 16 proteins are involved in cellular 
metabolic processes, as shown in Table 2. Other biological 
processes included those of multicellular organisms, e.g. 
biological regulation and response to stimuli. The proteins 
related to cell structure include those needed to build, e.g. 
organelles and macromolecules. Of the proteins related to 
molecular function, most are related to catalytic activity (22 
proteins); details are listed in Table 3. Other proteins are 
related to binding or oxidoreductase activity function. 
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Table 1  Protein annotation of PHN model 
Cat. Accession Uniprot AC Protein name Gene name Description 
Folder change ratio 
14 d/N 21 d/N 
A 
gi|4456766 P52759 UK114 Hrsp12, Psp1 perchloric acid soluble protein  0.0074  0.0108  
gi|195540087 B4F768 B4F768 Aldh4a1 LOC641316 Aldh4a1 protein  0.2834  0.7630  
gi|203237 P07171 CALB1 Calb1 calbindin-d28k  0.3257  0.2984  
gi|18426866 P13437 THIM Acaa2 3-ketoacyl-CoA thiolase, mitochondrial  0.3699  0.4622  
gi|11968102 P04182 OAT Oat ornithine aminotransferase, mitochondrial precursor  0.4172  0.5379  
gi|157823483 B0BNA5 COTL1 Cotl1, Clp coactosin-like protein  0.4255  0.6209  
gi|51260799 Q68FT4 Q68FT4 Suclg2 Suclg2 protein  0.4286  0.4441  
gi|6636119 Q9QXQ0 ACTN4 Actn4 alpha-actinin 4  0.4337  0.5823  
gi|37748456 Q64591 DECR Decr1, Decr 2,4-dienoyl CoA reductase 1, mitochondrial 0.4360  0.5160  
gi|157818027 D3ZZN3 D3ZZN3 Acss1, rCG_37494 acetyl-coenzyme A synthetase 2-like, mitochondrial  0.4393  0.5023  
gi|158081751 Q66HT1 Q66HT1 Aldob, rCG_60366 fructose-bisphosphate aldolase B  0.4505  0.8098  
gi|802111 Q63011 Q63011 MGC72973 zero beta-globin 0.4773  0.6468  
gi|40538860 Q9ER34 ACON Aco2 aconitate hydratase, mitochondrial precursor  0.4863  0.6475  
gi|76253725 Q3MHS9 Q3MHS9 Cct6a, rCG_21714 T-complex protein 1 subunit zeta  0.4927  0.4606  
gi|13242237 P63018 HSP7C Hspa8, Hsc70 Hsc73 heat shock cognate 71 kD protein 0.5872 0.3419 
gi|32189350 Q09073 ADT2 Slc25a5, Ant2 ADP/ATP translocase 2 0.4028 0.4346 
gi|58865994 Q6AYS2 Q6AYS2 Sfxn1, rCG_24191 sideroflexin-1 0.4429 0.4360 
gi|33086606 Q7TMC7 Q7TMC7 Tf Srprb Ab2-417  0.7389  0.4420  
B 
gi|149019103    rCG25753, isoform CRA_b  0.7333  1.6667  
gi|19705501 Q920P0 DCXR Dcxr, Glb L-xylulose reductase  0.9750  2.0833  
gi|8393446 P48508 GSH0 Gclm, Glclr glutamate—cysteine ligase regulatory subunit  0.9856  1.5379  
gi|1000439 P48721 GRP75 Hspa9, Grp75 Hspa9a grp75  0.9776 1.6098 
gi|6523793 Q9QYA6 Q9QYA6 Slc4a4, nbc electrogenic Na+ bicarbonate cotransporter  0.9900  1.5812  
gi|203033 P10719 ATPB Atp5b F1-ATPase beta subunit  1.2185  1.7899  
gi|76096348 Q3MIF4 XYLB Xylb xylulose kinase  1.3200  2.4300  
gi|149034221 G3V826 G3V826 Tkt, rCG_42377 transketolase, isoform CRA_a  1.4193  1.5625  
gi|149055818    rCG53940, isoform CRA_a  1.4390  1.7236  
gi|149020188    aldolase B, isoform CRA_a  1.4711  2.3388  
gi|149045753    rCG55135, isoform CRA_c 1.5639  2.1504  
gi|25742763 P06761 GRP78 Hspa5, Grp78 78 kD glucose-regulated protein precursor 1.5961 2.3973 
gi|149027328    alanine-glyoxylate aminotransferase 2, isoform CRA_c  1.6021  2.4187  
gi|25742748 P19468 GSH1 Gclc, Glclc glutamate—cysteine ligase catalytic subunit  2.2046  3.9274  
C 
gi|77628000 Q497B0 NIT2 Nit2 omega-amidase NIT2  1.5374  1.1864  
gi|13928690 P41562 IDHC Idh1 isocitrate dehydrogenase [NADP] cytoplasmic  1.5688  1.3028  
gi|220684 P13221 AATC Got1 cytosolic aspartate aminotransferase  1.5696  1.0949  
gi|110625641 Q7TP54 Q7TP54 Fam65b, RGD1306939 family with sequence similarity 65, member B 1.6062  1.4191  
gi|17865351 P46462 TERA Vcp transitional endoplasmic reticulum ATPase  1.7281  1.2094  
gi|71896574 Q9WUW8 ST1C2 Sult1c2 Sultk1 sulfotransferase 1C2  1.8846  1.7668  
gi|157822207 D4A2K1 D4A2K1 
Hoga1, RGD1310475_ 
predicted rCG_57749 
dihydrodipicolinate synthase-like, mitochondrial  1.9459  1.1041  
gi|155369281 A2VCW9 AASS Aass 
alpha-aminoadipic semialdehyde synthase, mitochondri-
al precursor 
2.4768  1.6490  
gi|1657632 P70619 GSHR Gsr glutathione reductase  2.8381  1.4945  
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Figure 1  All differentially expressed proteins were divided into three categories. (a) The expression of proteins was downregulated at day 14, but upregu-
lated at day 21. (b) The expression of proteins was downregulated at days 14 and 21. (c) The expression of proteins was upregulated at days 14 and 21.  
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Figure 2  GO analyses of all differentially expressed proteins. (a) There are 23 proteins involved in cellular components, 30 proteins in molecular function, 
and 22 proteins in biological processes. (b) Protein numbers in the subgroup of cellular components. (c) Protein numbers in the subgroup of molecular func-
tion. (d) Protein numbers in biological processes. 
2.4  Analyses of VCP protein 
Protein-GO networks of all proteins are provided in Figure 
S1. Combining these results, we analyzed the interaction of 
proteins using an MAS (Molecular Annotation System). 
VCP (fold change at day 14 was 1.7281, and 1.2094 at day 
21) interacted with many other proteins, suggesting that it 
plays an important role in the renal disease process. The 
VCP-GO networks are shown in Figure 3. The results indi-
cated that HSPa5, markers of ERS, could interact with VCP 
via slac2a4 (omitted in Table 1). We also extracted the de-
tailed GO function of VCP in Table 4, which showed that  
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Table 2  Cellular metabolic process related proteins 
Uniprot AC Protein name Gene Ontology (GO) 
P13221 AATC 2-oxoglutarate metabolic process; L-phenylalanine:2-oxoglutarate aminotransferase activity; axon terminus; biosynthetic 
process; carboxylic acid binding; cytosol; glutamate metabolic process; lysosome 
Q9ER34 ACON 3 iron, 4 sulfur cluster binding; 4 iron, 4 sulfur cluster binding; aconitate hydratase activity; citrate hydro-lyase (cis-aconitate-
forming) activity; citrate metabolic process; isocitrate hydro-lyase (cis-aconitate-forming) activity; isocitrate metabolic process 
P10719 ATPB 
ADP biosynthetic process; ATP binding; ATP hydrolysis coupled proton transport; ATP synthesis coupled proton transport;
calcium ion binding; rotational mechanism; lipoprotein particle receptor activity; mitochondrial proton-transporting ATP 
synthase complex 
Q920P0 DCXR D-xylose metabolic process; L-xylulose reductase (NADP
+) activity; glucose metabolic process; membrane; nucleotide bind-
ing; protein homotetramerization; xylulose metabolic process 
P48508 GSH0 glutamate metabolic process; glutamate-cysteine ligase activity; glutamate-cysteine ligase complex; glutathione biosynthetic 
process; negative regulation of neuron apoptosis; response to nitrosative stress; response to oxidative stress; soluble fraction 
P19468 GSH1 
ADP binding; anti-apoptosis; cell redox homeostasis; coenzyme binding; cysteine metabolic process; glutamate binding;
glutamate metabolic process; glutathione biosynthetic process; response to heat; response to hormone stimulus; response to 
oxidative stress 
P70619 GSHR 
NADP binding; cell redox homeostasis; cytosol; flavin adenine dinucleotide binding; glutathione binding; glutathione meta-
bolic process; glutathione-disulfide reductase activity; mitochondrion; protein homodimerization activity; soluble fraction; 
spermatogenesis 
P41562 IDHC 
2-oxoglutarate metabolic process; NAD binding; NADP binding; female gonad development; glyoxylate cycle; isocitrate
dehydrogenase (NADP+) activity; isocitrate metabolic process; magnesium ion binding; peroxisome; response to organic
cyclic compound  
P04182 OAT N2-acetyl-L-ornithine:2-oxoglutarate 5-aminotransferase activity; mitochondrial matrix; ornithine metabolic process; orni-
thine-oxo-acid transaminase activity; pyridoxal phosphate binding 
P13437 THIM acetyl-CoA C-acyltransferase activity; acetyl-CoA metabolic process; anti-apoptosis; fatty acid beta-oxidation; mitochondrial 
matrix 
Q3MIF4 XYLB ATP binding; D-xylose metabolic process; xylulokinase activity 
Q3MHS9 Q3MHS9 ATP binding; cytoplasm; protein folding; unfolded protein binding 
D3ZZN3 D3ZZN3 AMP binding; acetate biosynthetic process; acetate-CoA ligase activity; propionate biosynthetic process 
Q66HT1 Q66HT1 fructose-bisphosphate aldolase activity; glycolysis 
B4F768 B4F768 1-pyrroline-5-carboxylate dehydrogenase activity; mitochondrial matrix; oxidoreductase activity, acting on the aldehyde or
oxo group of donors, NAD or NADP as acceptor; proline biosynthetic process 
Q68FT4 Q68FT4 ATP binding; succinate metabolic process; succinate-CoA ligase activity; succinyl-CoA metabolic process; tricarboxylic acid 
cycle 
 
it likely has 14 functions, including ER to Golgi vesicle- 
mediated transport, proteasomal ubiquitin-dependent protein 
catabolism, and protein homooligomerization (Figure 3).  
2.5  mRNA and protein expression of VCP and HSPa5 
in the model 
In the LC-MS/MS results, the expression of the two proteins 
at days 14 and 21 is shown in Figure 4(a), which includes 
groups B and C. To verify expression of the two proteins in 
the three groups, we detected the mRNA and protein ex-
pression level using real-time PCR and Western blotting. 
The results (Figure 4(b) and (c)) indicated that at days 14 and 
21, the mRNA and protein expression level of VCP and 
HSPa5 were upregulated when compared to normal tissue. 
Although at day 21, the expression of VCP was downregu-
lated, the difference between the two time points was not 
statistically significant.  
2.6  Pathway analysis 
All significant pathways in which these differentially ex-
pressed proteins were involved are shown in Figure S1 and 
Table 5. The main pathways include glutathione metabolism, 
reductive carboxylate cycle (CO2 fixation), citrate cycle, 
arginine and proline metabolism, and control of genes in-
cluding Gclm, Gclc, Idh1, Gsr, Acss1, Aco2, Idh1, Suclg2, 
Aldh4a1, Oat, and Got1. We obtained the correlation of 
these pathway related proteins/genes, as shown in Figure 4. 
VCP and HSPa5 were involved in the same pathways. 
2.7  ERS of podocyte after inhibiting VCP  
After treatment of MPCs with tunicamycin for 10 h, the 
expression level of HSPa5, the ERS marker, was upregu-
lated, as shown in Figure 5. Expression of VCP also in-
creased. If cell VCP was inhibited by siRNA, HSPa5 ex-
pression did not change. After the cell RNAi was treated  
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Table 3  Catalytic activity related proteins 
Uniprot AC Protein name Gene Ontology (GO) 
A2VCW9 AASS mitochondrion; nucleotide binding; saccharopine dehydrogenase (NAD
+, L-glutamate-forming) activity; saccharopine dehy-
drogenase (NADP+, L-lysine-forming) activity 
P13221 AATC 2-oxoglutarate metabolic process; cytosol; glutamate metabolic process; lysosome; pyridoxal phosphate binding; soluble fraction 
Q9ER34 ACON 3 iron, 4 sulfur cluster binding; 4 iron, 4 sulfur cluster binding; isocitrate metabolic process; mitochondrion; protein binding; 
tricarboxylic acid cycle 
P10719 ATPB ADP biosynthetic process; ATP binding; ATP hydrolysis coupled proton transport; mitochondrial proton-transporting ATP 
synthase complex, catalytic core F(1) 
Q920P0 DCXR D-xylose metabolic process; L-xylulose reductase (NADP
+) activity; glucose metabolic process; membrane; nucleotide bind-
ing; protein homotetramerization; xylulose metabolic process 
Q64591 DECR 2,4-dienoyl-CoA reductase (NADPH) activity; mitochondrion 
P48508 GSH0 
glutamate metabolic process; glutamate-cysteine ligase activity; glutamate-cysteine ligase catalytic subunit binding; gluta-
mate-cysteine ligase complex; glutathione biosynthetic process; negative regulation of neuron apoptosis; response to oxidative 
stress; soluble fraction 
P19468 GSH1 
ADP binding; anti-apoptosis; cell redox homeostasis; coenzyme binding; cysteine metabolic process; glutamate binding; glu-
tamate-cysteine ligase complex; glutathione biosynthetic process; magnesium ion binding; negative regulation of neuron apop-
tosis; response to oxidative stress 
P70619 GSHR 
NADP binding; cell redox homeostasis; cytosol; flavin adenine dinucleotide binding; glutathione binding; glutathione meta-
bolic process; glutathione-disulfide reductase activity; mitochondrion; protein homodimerization activity; soluble fraction; 
spermatogenesis 
P41562 IDHC 2-oxoglutarate metabolic process; NAD binding; peroxisome; response to organic cyclic compound; response to steroid hor-
mone stimulus; soluble fraction; tricarboxylic acid cycle 
Q497B0 NIT2 nitrogen compound metabolic process; omega-amidase activity 
P04182 OAT N2-acetyl-L-ornithine:2-oxoglutarate 5-aminotransferase activity; mitochondrial matrix; ornithine metabolic process; orni-
thine-oxo-acid transaminase activity; pyridoxal phosphate binding 
Q9WUW8 ST1C2 lysosome; sulfotransferase activity 
P46462 TERA 
ATP binding; ATPase activity; ER to Golgi vesicle-mediated transport; cytosol; endoplasmic reticulum; identical protein bind-
ing; lipid binding; microsome; nucleus; positive regulation of proteasomal ubiquitin-dependent protein catabolic process; pro-
tein homooligomerization; receptor binding 
P13437 THIM acetyl-CoA C-acyltransferase activity; acetyl-CoA metabolic process; anti-apoptosis; fatty acid beta-oxidation; mitochondrial 
matrix 
P52759 UK114 endonuclease activity; mitochondrion; nucleus; peroxisome 
Q3MIF4 XYLB ATP binding; D-xylose metabolic process; xylulokinase activity 
D4A2K1 D4A2K1 lyase activity 
Q7TP54 Q7TP54 cellular iron ion homeostasis; ferric iron binding; oxidoreductase activity 
D3ZZN3 D3ZZN3 AMP binding; acetate biosynthetic process; acetate-CoA ligase activity; propionate biosynthetic process 
Q66HT1 Q66HT1 fructose-bisphosphate aldolase activity; glycolysis 
B4F768 B4F768 1-pyrroline-5-carboxylate dehydrogenase activity; mitochondrial matrix; oxidoreductase activity, acting on the aldehyde or oxo
group of donors, NAD or NADP as acceptor; proline biosynthetic process 
 
with tunicamycin, the VCP expression level was lower than 
that of the group treated with only tunicamycin, but the 
HSPa5 expression level was significantly higher. 
3  Discussion 
Membranous glomerulonephritis (MGN) accounts for ap-
proximately 30% of cases of nephrotic syndrome in adults, 
with peak incidence between the ages of 30 and 50 years 
and a male to female ratio of 2:1 [19]. Major contributions 
to our current understanding of the disease come from 
Heymann nephritis, a rat model of MGN [20]. The patho-
logical features of membranous nephropathy are uniform 
and consistent incrassation of the glomerular capillary base-
ment membrane, and diffuse subepithelial immune complex 
deposition. An obvious increase in proteinuria was observed 
in the pHN by day 14 and it peaked on day 21; on this day, 
interstitial fibrosis appeared [21]. Therefore, we selected 
days 14 and 21 as the two time points of the pHN model to 
analyze the differential protein expression profile using la-
bel-free LC-MS/MS. Proteomics applied at a large scale 
may provide useful diagnostic information. Several reports 
on MN have focused on the urine for diagnostic purposes  
 Huang Z Y, et al.   Chin Sci Bull   July (2012) Vol.57 No.20 2501 
 
Figure 3  Protein-GO networks and interaction with VCP. (a) Significant molecular function network of VCP. (b) Significant biological process network of 
VCP. (c) Significant cellular component network of VCP. (d) Interaction graph of VCP; the numbers represent the frequency of interaction.  
 
Figure 4  Verification of VCP and HSPa5 in LC-MS/MS by real-time PCR and Western blotting. (a) The degree of change of VCP and HSPa5 on days 14 
and 21 in the pHN model detected by LC-MS/MS. (b) Real-time PCR determined the mRNA expression level of VCP and HSPa5; at days 14 and 21, the two 
proteins showed increased expression, and significant differences were observed between days 14 and 21 compared to normal tissue. *P < 0.05, n = 3. (c) 
Western blotting determined the protein expression level of VCP and HSPa5; at days 14 and 21, the two proteins showed increased expression, and signifi-
cant differences were observed between days 14 and 21 compared to normal tissue. *P < 0.05, n = 3.  
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Table 4  The detailed GO analysis of VCP protein (GI:1786535) 
Molecular function Biological process Cellular component 
GO:0000166 nucleotide binding  
GO:0006810 transport  
GO:0005634 nucleus  
GO:0005515 protein binding GO:0005737 cytoplasm 
GO:0005524 ATP binding GO:0006888 ER to Golgi vesicle-mediated transport GO:0005783  
GO:0008289 lipid binding GO:0043161 proteasomal ubiquitin-dependent protein catabolism endoplasmic reticulum 
GO:0016787 hydrolase activity 
GO:0051260 protein homooligomerization 
GO:0005792  
GO:0016887 ATPase activity microsome 
Table 5  Pathway information of differentially expressed proteinsa) 
Pathway Count P-value Q-value Gene GI number 
Glutathione metabolism 4 3.36×108 1.68×108 Gclm; Gclc; Idh1; Gsr 8393446; 25742748; 13928690; 1657632 
Reductive carboxylate cycle (CO2 fixation) 3 5.21×108 2.08×108 Acss1; Aco2; Idh1 157818027; 40538860;13928690 
Citrate cycle (TCA cycle) 3 1.74×106 5.81×107 Suclg2; Aco2; Idh1 51260799; 40538860; 13928690 
Arginine and proline metabolism 3 2.13×106 6.08×107 Aldh4a1; Oat; Got1 195540087; 11968102; 220684 
Pentose phosphate pathway 2 1.63×104 2.52×105 Aldob; Tkt; Aldob 158081751; 149034221; 149020188 
Glutamate metabolism 2 1.77×104 2.52×105 Aldh4a1; Got1 195540087; 220684 
Alanine and aspartate metabolism 2 2.22×104 2.62×105 Agxt2; Got1 149027328; 220684 
Propanoate metabolism 2 2.73×104 3.03×105 Suclg2; Acss1 51260799; 157818027 
Glycolysis/Gluconeogenesis 2 0.002702 2.46×104 Acss1; Aldob; Aldob 157818027; 158081751; 149020188 
Antigen processing and presentation 2 0.002866 2.49×104 Hspa8; Hspa5 13242237; 25742763 
Alkaloid biosynthesis I 1 0.004703 3.62×104 Got1 220684 
Fatty acid elongation in mitochondria 1 0.007827 4.89×104 Acaa2 18426866 
Phenylalanine, tyrosine and tryptophan  
biosynthesis 
1 0.007827 4.89×104 Got1 220684 
Glyoxylate and dicarboxylate metabolism 1 0.008607 4.92×104 Aco2 40538860 
Parkinson’s disease 2 0.008613 4.92×104 Slc25a5; Atp5b 32189350; 203033 
Cysteine metabolism 1 0.010164 5.56×104 Got1 220684 
Phenylalanine metabolism 1 0.010942 5.61×104 Got1 220684 
Pentose and glucuronate interconversions 1 0.017142 7.79×104 Xylb 76096348 
Bile acid biosynthesis 1 0.018686 8.21×104 Acaa2 18426866 
Tyrosine metabolism 1 0.023305 9.51×104 Got1 220684 
Fructose and mannose metabolism 1 0.024839 9.94×104 Aldob; Aldob 158081751; 149020188 
Pyruvate metabolism 1 0.028666 0.001102553 Acss1 157818027 
Fatty acid metabolism 1 0.031718 0.001185701 Acaa2 18426866 
Glycine, serine and threonine metabolism 1 0.031718 0.001185701 Agxt2 149027328 
Valine, leucine and isoleucine degradation 1 0.034759 0.001241406 Acaa2 18426866 
Adherens junction 1 0.055052 0.001931646 Actn4 6636119 
Leukocyte transendothelial migration 1 0.087242 0.002814248 Actn4 6636119 
Tight junction 1 0.095122 0.002860587 Actn4 6636119 
Systemic lupus erythematosus 1 0.105057 0.002959349 Actn4 6636119 
Oxidative phosphorylation 1 0.117675 0.003159073 Atp5b 203033 
Focal adhesion 1 0.137645 0.003536344 Actn4 6636119 
Calcium signaling pathway 1 0.139006 0.003536344 Slc25a5 32189350 
Regulation of actin cytoskeleton 1 0.149147 0.003699245 Actn4 6636119 
Alzheimer’s disease 1 0.178885 0.004160114 Atp5b 203033 
MAPK signaling pathway 1 0.185356 0.004179774 Hspa8 13242237 
a) P-value: we calculate the P value using a hypergeometric distribution. The genes are enriched significantly in the pathway when P value< 0.05. Q value: 
Q is Fasle Discovery Rate (FDR), Q default 0.05, the less the Q is, the more significant the genes (or proteins) enriched in the one pathway (or GO term), 
and the less FDR.  
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Figure 5  VCP was inhibited by RNAi, and ERS was induced by tunicamycin (Tm). MPCs were pretreated with 10 g/mL Tm for 10 h to induce ERS; the 
expression levels of VCP and HSPa5 were both upregulated, and significant differences were observed compared with the control. *P < 0.05, n = 3. MPCs 
were transfected with siRNA and VCP protein expression was inhibited (†P < 0.05, n = 3), but HSPa5 expression did not change. Cells were transfected with 
siRNA of VCP and treated with Tm; HSPa5 expression increased, and a significant difference was observed between the Tm and Tm+siRNA groups (‡P < 
0.05, n = 3), although VCP expression was considerable in the control. 
[22,23]. However, few reports have analyzed the differen-
tially expressed proteins in the development of MN. Our 
objective was to identify the differentially expressed pro-
teins seen in the pHN rat model. The results identified 41 
differentially expressed proteins among three groups (day 0, 
day 14, and day 21). According to their expression changes, 
we divided them into three categories, A, B, and C. Proteins 
in group A were downregulated at day 14, but upregulated 
at day 21; group B showed downregulation at days 14 and 
21; and group C showed upregulation at days 14 and 21. 
These proteins played an important role in the cellular pro-
cess and biological regulation (listed in Table 1). The 16 
proteins related to cellular metabolism were the predomi-
nant components. Since ERS profoundly affects metabolic 
processes [24], our findings strongly suggest that ERS on 
these proteins might be one of the most important biological 
events at day 14 or 21 in the PHN rat model. In the ERS 
process, misfolded protein in the ER would be degraded in 
the cytoplasm by catalytic proteins [25–27]. Table 3 lists the 
catalytic proteins (22) and their GO terms. These proteins 
affect the ERS process. 
HSPa8 and HSPa5, the proteins needed for cellular me-
tabolism, belong to the heat-shock protein family, and can 
bind to nascent polypeptides to facilitate correct folding 
[28,29]. They also function as an ATPase in the disassem-
bly of clathrin-coated vesicles during transport of mem-
brane components through the cell [30,31]. VCP, the cata-
lytic protein, belongs to a family that includes putative 
ATP-binding proteins involved in vesicle transport and fu-
sion, 26S proteasome function, and assembly of peroxi-
somes [32]. It also binds with clathrin and heat-shock protein 
Hsc70 to form a complex [33]. Additionally, it has been 
implicated in several other cellular events related to mitosis, 
including homotypic membrane fusion and ubiquitin-de-     
pendent protein degradation [34–36]. Our results indicate 
that most differentially expressed proteins could interact 
with each other, as shown in Figure 2, and among these, 
VCP could interact with HSPa8 or HSPa5 via slc2a4. Re-
grettably, our LC-MS/MS did not provide evidence of a 
significant change in slc24a expression. Our findings sug-
gest that the cell processes mediated by VCP affect the de-
velopment of MN.  
Research indicates that the basic mechanism of MN is 
complement-mediated injury of the podocyte and its slit- 
pore membrane [37,38] and that ERS is the main cause of 
podocyte injury [39,40]. HSPa8 and HSPa5 are considered 
the markers of ERS increase [41–43], and VCP is an inte-
gral component of the ER-associated degradation and cellu-
lar stress pathways [44,45]. The detailed GO analysis of 
VCP in our study agreed with this finding (Table 4), and the 
pathway analyses showed VCP and HSPa5 to be in the 
same functional pathway. Therefore, we hypothesized that 
ERS, with VCP as a mediator, is an important trigger of 
podocyte injury in MN. 
To test this theory, we cultured MPCs and induced ERS 
with tunicamycin, knocking down the expression level by 
RNAi. Results suggested when VCP of cells was knocked 
down under normal conditions, the ERS did not change, but 
VCP knockdown could increase ERS significantly after 
treatment with tunicamycin. Gp78-VCP interaction may 
represent one means of degradation of ER-associated deg-
radation substrates [46]. VCP is required for maintenance of 
normal ER structure and function and mediates the degrada-
tion of certain proteins [47]. This supports our results that 
under normal conditions, the podocyte ERS is unaffected by 
VCP, but under stress, VCP may be activated to degrade 
unfolded proteins. 
In conclusion, ERS plays an important role in podocyte 
injury of MN, and it is mediated via the HSPa5-VCP sig-
naling pathway. In this process, the cellular metabolism 
proteins and catalytic proteins were predominant. 
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